ReviewJournal of leukocyte biology2015
Interferon at the crossroads of allergy and viral infections.
Review in Journal of leukocyte biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- Prevalence of Comorbid Asthma and Related Outcomes in COVID-19: A Systematic Review and Meta-Analysis.The journal of allergy and clinical immunology. In practice · 2021Pooled it
- Article
- Exploring the Potential Benefits of Biologic Therapies Beyond Respiratory Allergy.ImmunoTargets and therapy · 2026Review
- Unraveling mechanisms of allergen sensitization and allergic rhinitis via the nasal transcriptome.The Journal of allergy and clinical immunology · 2026Article
- DNA methylation of food sensitization in a French-Canadian population.Clinical epigenetics · 2025Article
- Lung Gene Expression Suggests Roles for Interferon-Stimulated Genes and Adenosine Deaminase Acting against RNA-1 in Pathologic Responses to Diisocyanate.Chemical research in toxicology · 2024Article
- Identification of cow milk epitopes to characterize and quantify disease-specific T cells in allergic children.The Journal of allergy and clinical immunology · 2023Article
- Omalizumab prevents respiratory illnesses in non-atopic chronic spontaneous urticaria patients: A prospective, parallel-group, pilot pragmatic trial.Clinical and translational allergy · 2023Article
- Sialokinin in mosquito saliva shifts human immune responses towards intracellular pathogens.PLoS neglected tropical diseases · 2023Article
- Review
- Tollip deficiency exaggerates airway type 2 inflammation in mice exposed to allergen and influenza A virus: role of the ATP/IL-33 signaling axis.Frontiers in immunology · 2023Article
- The role of gut microbiome in the complex relationship between respiratory tract infection and asthma.Frontiers in microbiology · 2023Review
- Hypersensitivity may be involved in severe COVID-19.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2022Article
- A bird's eye view on the role of dendritic cells in SARS-CoV-2 infection: Perspectives for immune-based vaccines.Allergy · 2022Review
- Profile of coronavirus disease enlightened asthma as a protective factor against death: An epidemiology study from Brazil during the pandemic.Frontiers in medicine · 2022Article
- SARS-CoV-2-Specific Adaptive Immunity in COVID-19 Survivors With Asthma.Frontiers in immunology · 2022Article
- ISR8/IRF1-AS1 Is Relevant for IFNα and NF-κB Responses.Frontiers in immunology · 2022Article
- The Interactions Between Autoinflammation and Type 2 Immunity: From Mechanistic Studies to Epidemiologic Associations.Frontiers in immunology · 2022Review
- Disease Tolerance during Viral-Bacterial Co-Infections.Viruses · 2021Review
- Effect modification by age of the association between obstructive lung diseases, smoking, and COVID-19 severity.BMJ open respiratory research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
IFN-α/β was first described as a potent inhibitor of viral replication, but it is now appreciated that IFN signaling plays a pleiotropic role in regulating peripheral T cell functions. Recently, IFN-α/β was shown to block human Th2 development by suppressing the transcription factor GATA3. This effect is consistent with the role for IFN-α/β in suppressing allergic inflammatory processes by blocking granulocyte activation and IL-4-mediated B cell isotype switching to IgE. With the consideration of recent studies demonstrating a defect in IFN-α/β secretion in DCs and epithelial cells from individuals with severe atopic diseases, there is an apparent reciprocal negative regulatory loop in atopic individuals, whereby the lack of IFN-α/β secretion by innate cells contributes to the development of allergic Th2 cells. Is it possible to overcome these events by treating with IFN-α/β or by inducing its secretion in vivo? In support of this approach, case studies have documented the therapeutic potential of IFN-α/β in treating steroid-resistant allergic asthma and other atopic diseases. Additionally, individuals with asthma who are infected with HCV and respond to IFN therapy showed a reduction in symptoms and severity of asthma attacks. These findings support a model, whereby allergic and antiviral responses are able to cross-regulate each other, as IgER cross-linking of pDCs prevents IFN-α/β production in response to viral infection. The clinical importance of upper-respiratory viruses in the context of allergic asthma supports the need to understand how these pathways intersect and to identify potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.